Filing Details

Accession Number:
0000899243-22-039217
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-22 16:42:42
Reporting Period:
2022-12-20
Accepted Time:
2022-12-22 16:42:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590750 Viridian Therapeutics Inc. VRDN Services-Medical Laboratories (8071) 471187261
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1883986 Lara Meisner C/O Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham MA 02453
General Counsel And Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-20 600 $23.03 600 No 4 M Direct
Common Stock Disposition 2022-12-20 600 $28.07 0 No 4 S Direct
Common Stock Acquisiton 2022-12-21 16,326 $23.03 16,326 No 4 M Direct
Common Stock Disposition 2022-12-21 16,326 $29.19 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-12-20 600 $0.00 600 $23.03
Common Stock Stock Option (Right to Buy) Disposition 2022-12-21 16,326 $0.00 16,326 $23.03
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
61,047 2031-09-22 No 4 M Direct
44,721 2031-09-22 No 4 M Direct
Footnotes
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.